COVID-19 Vaccines and Myocarditis: What Scientists Are Learning

mRNA vaccination can, in relatively rare cases, trigger a spectrum of immune-mediated cardiac effects ranging from transient myocardial inflammation and biomarker elevation to clinically apparent myocarditis, with fulminant myocarditis representing the most severe but least common manifestation

A new Stanford Medicine study sheds light on a long-standing question: why do mRNA-based COVID-19 vaccines could cause myocarditis, particularly in young males? Importantly, the findings also point toward possible ways to reduce this risk without undermining vaccine effectiveness.

The researchers identified a two-step immune reaction behind vaccine-associated myocarditis. After vaccination, macrophages (frontline immune cells) release a signaling protein called CXCL10. This, in turn, activates T cells, which produce another inflammatory molecule, interferon-gamma (IFN-γ). Together, these cytokines act as a “tag team,” driving inflammation that can directly injure heart muscle cells and attract additional immune cells into cardiac tissue.

In mouse models and lab-grown human heart tissue, elevated CXCL10 and IFN-γ

levels led to classic signs of heart injury, including increased cardiac troponin. Blocking these cytokines reduced inflammation and preserved heart function, while largely maintaining the immune response needed for protection against COVID-19.

Crucially, the study reinforces that vaccine-associated myocarditis is rare and usually mild, with most patients recovering fully and quickly. Rates peak in males under 30, particularly after a second dose, but even so, COVID-19 infection itself is about 10 times more likely to cause myocarditis than vaccination.

The researchers also explored a potential mitigating strategy: genistein, a soy-derived compound with mild estrogen-like, anti-inflammatory effects. In experiments, genistein reduced cytokine-driven heart inflammation in cells and animals, hinting at a possible preventive approach that warrants further clinical study.

These findings align with a growing body of peer-reviewed research worldwide. Recent Canadian and international studies confirm that myocarditis and pericarditis following mRNA vaccination are real although still considered uncommon, tend to be less severe than cases seen after COVID-19 infection, and involve complex immune mechanisms: including cytokine signaling, molecular mimicry, and T-cell targeting of heart tissue.

Hopefully there will be more studies to deepen scientific understanding of adverse effects and open the door to smarter vaccine designs and targeted strategies to make vaccines even safer.

REFERENCES

Cao X, Manhas A, Chen YI, Caudal A, Mondejar-Parreño G, Zhu W, Liu W, Kong X, Zeng W, Liu L, Zhao SR, Jahng JWS, Utz PJ, Nadeau KC, Nishiga M, Wu JC. Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination. Sci Transl Med. 2025 Dec 10;17(828):eadq0143. doi: 10.1126/scitranslmed.adq0143. Epub 2025 Dec 10. PMID: 41370400.

Piché-Renaud PP, Buchan CA, Burton C, Chapdelaine H, Jeewa A, Morris SK, Pernica JM, Pham-Huy A, Sadarangani M, Salvadori MI, Suresh S, Kafil TS, Cowan J, Top KA; Special Immunization Clinic Network investigators. Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study. Vaccine. 2026 Jan 5;70:128016. doi: 10.1016/j.vaccine.2025.128016. Epub 2025 Nov 28. PMID: 41317434.

Piché-Renaud P.P., Buchan C.A., Burton C., Chapdelaine H., Jeewa A., Morris S.K., Pernica J.M., Pham-Huy A., Sadarangani M., Salvadori M.I., Suresh S., Kafil T.S., Cowan J., Top K.A.; Special Immunization Clinic Network investigators. Revaccination of individuals with cardiac adverse events following COVID-19 vaccination: A Canadian Immunization Research Network study. Vaccine. 2026 Jan 5;70:128016. doi:10.1016/j.vaccine.2025.128016 PMID: 41317434

Top K.A., Bettinger J.A., Embree J.E., Jadavji T., Purewal R., Sauvé L., Papenburg J., Deeks S.L., Wilson S.E., Dahdah N., Sadarangani M., Halperin S.A., Kakkar F., Morris S.K.; IMPACT Investigators.  Active Surveillance for Myocarditis and Pericarditis in Canadian Children from 2021 to 2022: A Canadian Immunization Monitoring Program ACTive Study. Journal of Pediatrics. 2025 Sep;284:114642. doi:10.1016/j.jpeds.2025.114642 PMID: 40373954

Wang J., Sun X.Y., Gao Q., Fu M., Xiao M., Du N., Ge X.Y. Exploring ceRNA mechanisms in COVID-19 mRNA vaccine-induced myocarditis: implications for future vaccine design. Frontiers in Immunology. 2025 Oct 22;16:1674049. doi:10.3389/fimmu.2025.1674049 PMID: 41200189 PMCID: PMC12586086

Fanti S, Dyer C, Ingimarsdóttir IJ, Harding D, Wang G, D'Amati A, Shahaj E, Sigurbergsdóttir AÝ, Thórsdóttir H, Gunnarsdóttir OB, Kanoni S, Wright P, Martin J, Chorlton J, Hollowood Z, Brynjólfsson SF, Lúdvíksson BR, Solito E, Bert S, Keane JM, Mohiddin SA, Longhi MP, Marelli-Berg FM. Combined Adaptive Immune Mechanisms Mediate Cardiac Injury After COVID-19 Vaccination. Circulation. 2025 Nov 25;152(21):1485-1500. doi: 10.1161/CIRCULATIONAHA.125.074644. Epub 2025 Oct 30. PMID: 41164857; PMCID: PMC12643570.

Jiang Y, Xie Y, You Y, Han B. Mechanistic insights into COVID-19 mRNA vaccine-associated myocarditis: a bioinformatics analysis. Am J Transl Res. 2025 Mar 15;17(3):2339-2351. doi: 10.62347/CCVM6311. PMID: 40226040; PMCID: PMC11982872.